Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 325-330

  Masago, Katsuhiro ^a   Fujita, Shiro ^b   Kim, Young Hak ^a   Hatachi, Yukimasa ^a   Fukuhara, Akiko ^a   Irisa, Kaoru ^a   Nagai, Hiroki ^a   Sakamori, Yuichi ^a   Togashi, Yosuke ^a   Mio, Tadashi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Gemcitabine; Nedaplatin; Phase I; Squamous cell lung cancer

Indexed keywords

GEMCITABINE; NEDAPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; HEMATOLOGIC DISEASE; LUNG TUMOR; MIDDLE AGED; SQUAMOUS CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79953805329     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1321-1     Document Type: Article

References (27)

1. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. J Clin Oncol 26:60-65
2. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H (2002) Rowinsky EK: Zd1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:2240-2250 (Pubitemid 34441651)
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
4. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M (1990) Nephrotoxicity of a new platinum compound, 254-s, evaluated with rat kidney cortical slices. Toxicol Lett 52:15-24 (Pubitemid 20175398)
5. Ota K, Wakui A, Majima H, Niitani H, Inuyama Y, Ogawa M, Ariyoshi Y, Yoshida O, Taguchi T, Kimura I et al (1992) Phase I study of a new platinum complex 254-s, cis-diammine (glycolato)-platinum (ii). Gan To Kagaku Ryoho 19:855-861
6. Kelsen DP, Scher H, Alcock N, Leyland-Jones B, Donner A, Williams L, Greene G, Burchenal JH, Tan C, Philips FS, Young CW (1982) Phase I clinical trial and pharmacokinetics of 40-carboxyphthalato (1, 2-diaminocyclohexane) platinum (ii). Cancer Res 42:4831-4835 (Pubitemid 13206002)
7. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolate-o, o′) diammineplatinum (ii), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393-396 (Pubitemid 20333740)
8. Furuse K, Fukuoka M, Asamoto H, Niitani H, Kimura I, Sakuma A, Yamaguchi y (1992) a randomized comparative study of 254-s plus vindesine (vds) vs. Cisplatin (cddp) plus vds in patients with advanced non-small cell lung cancer (nsclc). Gan To Kagaku Ryoho 19:1019-1026
9. Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6 (Suppl 6):7-13 (Pubitemid 26014890)
10. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL (2001) Clinical-benefit response in advanced nonsmall-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221-1230 (Pubitemid 32994749)
11. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J (2000) Gemcitabine plus best supportive care (bsc) vs bsc in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. Uk nsclc gemcitabine group. Non-small cell lung cancer. Br J Cancer 83:447-453 (Pubitemid 30487855)
12. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1821-1826 (Pubitemid 24349383)
13. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M, Voi M (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32 A: 243-248
14. Sandler A, Ettinger DS (1999) Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4:241-251
15. Iaffaioli RV, Tortoriello A, Facchini G, Caponigro F, Gentile M, Marzano N, Gravina A, Dimitri P, Costagliola G, Ferraro A, Ferrante G, De Marino V, Illiano A (1999) Phase I-II study of gemcitabine and carboplatin in stage iiib-iv non-small-cell lung cancer. J Clin Oncol 17:921-926 (Pubitemid 29109324)
16. Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, Saijo N (1991) Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother Pharmacol 27:263 270
17. Ikeda M, Maekawa R, Tanaka H, Matsumoto M, Takeda Y, Tamura Y, Nemori R, Yoshioka T (2000) Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clin Cancer Res 6:3290-3296 (Pubitemid 30637759)
18. Matsumoto M, Takeda Y, Maki H, Hojo K, Wada T, Nishitani Y, Maekawa R, Yoshioka T (2001) Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn J Cancer Res 92:51-58 (Pubitemid 32175478)
19. Takeda Y, Wada T, Nishitani Y, Matsumoto M, Hojo K, Maekawa R, Yoshioka T (2002) Preclinical combination chemotherapy of nedaplatin with gemcitabine against gemcitabinerefractory human lung cancer. Cancer Lett 182:61-68 (Pubitemid 34518657)
20. Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M (2009) Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. BMC Cancer 9:408
21. Masters GA, Argiris AE, Hahn EA, Beck JT, Rausch PG, Ye Z, Monberg MJ, Bloss LP, Curiel RE, Obasaju CK (2006) A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-smallcell lung cancer. J Thorac Oncol 1:19-24 (Pubitemid 47177191)
22. Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Bonifazi V, Orlandini C, Franco Conte P (2000) A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Cancer 89:1714-1719
23. Hirose T, Horichi N, Ohmori T, Shirai T, Sohma S, Yamaoka T, Ohnishi T, Adachi M (2003) Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer. Lung Cancer 39:91-97 (Pubitemid 36020300)
24. Kurata T, Tamura K, Yamamoto N, Nogami T, Satoh T, Kaneda H, Nakagawa K, Fukuoka M (2004) Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 90:2092-2096 (Pubitemid 38869711)
25. Shirai T, Hirose T, Noda M, Ando K, Ishida H, Hosaka T, Ozawa T, Okuda K, Ohnishi T, Ohmori T, Horichi N, Adachi M (2006) Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung Cancer 52:181-187
26. Niioka T, Uno T, Yasui-Furukori N, Takahata T, Shimizu M, Sugawara K, Tateishi T (2007) Pharmacokinetics of low-dose nedaplatin and validation of auc prediction in patients with nonsmall-cell lung carcinoma. Cancer Chemother Pharmacol 59:575-580 (Pubitemid 46295121)
27. Yamamoto N, Tamura T, Kurata T, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Saijo N (2009) A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65:79-88